Abstract:Liquid biopsy methodologies, for the purpose of plasma genotyping of cell-free DNA (cfDNA) of solid tumors, are a new class of novel molecular assays. Such assays are rapidly entering the clinical sphere of research-based monitoring in translational oncology, especially for thoracic malignancies. Potential applications for these blood-based cfDNA assays include: (i) initial diagnosis, (ii) response to therapy and follow-up, (iii) tumor evolution, and (iv) minimal residual disease evaluation. Precision medicine will benefit from cutting-edge molecular diagnostics, especially regarding treatment decisions in the adjuvant setting, where avoiding over-treatment and unnecessary toxicity are paramount. The use of innovative genetic analysis techniques on individual patient tumor samples is being pursued in several advanced clinical trials. Rather than using a categorical treatment plan, the next critical step of therapeutic decision making is providing the "right" cancer therapy for an individual patient, including correct dose and timeframe based on the molecular analysis of the tumor in question. Per the 21st Century Cures Act, innovative clinical trials are integral for biomarker and drug development. This will include advanced clinical trials utilizing: (i) innovative assays, (ii) molecular profiling with cutting-edge bioinformatics, and (iii) clinically relevant animal or tissue models. In this paper, a mini-review addresses state-of-the-art liquid biopsy approaches. Additionally, an on-going advanced clinical trial for lung cancer with novelty through synergizing liquid biopsies, co-clinical trials, and advanced bioinformatics is also presented. Impact statement Liquid biopsy technology is providing a new source for cancer biomarkers, and adds new dimensions in advanced clinical trials. Utilizing a non-invasive routine blood draw, the liquid biopsy provides abilities to address perplexing issues of tumor tissue heterogeneity by identifying mutations in both primary and metastatic lesions. Regarding the assessment of response to cancer therapy, the liquid biopsy is not ready to replace medical imaging, but adds critical new information; for instance, through a temporal assessment of quantitative circulating tumor DNA (ctDNA) assay results, and importantly, the ability to monitor for signs of resistance, via emerging clones. Adjuvant therapy may soon be considered based on a quantitative cfDNA assay. As sensitivity and specificity of the technology continue to progress, cancer screening and prevention will improve and save countless lives by finding the cancer early, so that a routine surgery may be all that is required for a definitive cure.

Beyond blood: Advancing the frontiers of liquid biopsy in oncology and personalized medicine

Liquid biopsy for human cancer: cancer screening, monitoring, and treatment

Liquid biopsy: a step closer to transform diagnosis, prognosis and future of cancer treatments

Liquid biopsy and its role in an advanced clinical trial for lung cancer

Liquid Biopsy in the Clinical Management of Cancers

Liquid biopsies for cancer: From bench to clinic

Liquid biopsy in cancer current: status, challenges and future prospects

Liquid biopsy: current technology and clinical applications

Application of liquid biopsy in precision medicine: opportunities and challenges

Liquid biopsy for early cancer detection: technological revolutions and clinical dilemma

Liquid biopsy, an innovation of modern medicine

Liquid biopsy: paving a new avenue for cancer research

Latest Research Progress of Liquid Biopsy in Tumor-A Narrative Review

Current and future opportunities for liquid biopsy of circulating biomarkers to aid in early cancer detection

The Liquid Biopsy Consortium: Challenges and Opportunities for Early Cancer Detection and Monitoring

Liquid Biopsies, Novel Approaches and Future Directions

Refining Cancer Management Using Integrated Liquid Biopsy

Advances in early detection methods for solid tumors

The Emerging Role of Liquid Biopsies in Revolutionising Cancer Diagnosis and Therapy

Liquid biopsy: a step forward towards precision medicine in urologic malignancies

State-of-the-art Nanotechnologies for the Detection, Recovery, Analysis and Elimination of Liquid Biopsy Components in Cancer